ANI Pharmaceuticals 過去の業績
過去 基準チェック /26
ANI Pharmaceuticalsは、平均年間53.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.7% 31.3%収益成長率で 成長しています。 ANI Pharmaceuticalsの自己資本利益率は16.4%であり、純利益率は9.1%です。
主要情報
53.48%
収益成長率
54.96%
EPS成長率
| Pharmaceuticals 業界の成長 | 5.95% |
| 収益成長率 | 31.29% |
| 株主資本利益率 | 16.39% |
| ネット・マージン | 9.09% |
| 前回の決算情報 | 31 Mar 2026 |
最近の業績更新
Recent updates
ナラティブの更新 • May 13
ANIP: Higher Margin Outlook Will Support Bullish Case Over Coming Years
Analysts have maintained their $90.00 price target on ANI Pharmaceuticals, citing updated assumptions around slightly different revenue growth, a higher profit margin, and a lower future P/E as the main factors supporting the unchanged view. What's in the News Raised full year 2026 revenue guidance to a range of US$1.08b to US$1.14b, compared with prior guidance of US$1.055b to US$1.115b (company guidance).ナラティブの更新 • Apr 24
ANIP: 2026 Revenue Guidance And New Launches Will Support Upside Potential
Analysts have kept their $90.00 price target for ANI Pharmaceuticals unchanged, citing relatively steady assumptions for revenue growth, profit margins, and future P/E as the basis for this view. What's in the News Launched Pimozide Tablets 1 mg and 2 mg, a generic version of Orap, with U.S. annual sales for the category of about US$3.1 million based on February 2026 IQVIA data (Key Developments).Seeking Alpha • Apr 10
ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
Summary ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category. Cortrophin has an extremely promising multi-indication potential, as well as plans for a prefilled syringe launch supported by another Phase 4 gout study. On balance, I think ANIP’s valuation seems exceedingly cheap relative to its stable revenue growth and positive cash flows, which is why I rate the stock a “Buy”. Read the full article on Seeking Alphaナラティブの更新 • Apr 08
ANIP: 2026 Revenue Guidance Will Test Confidence In Margin Assumptions
Analysts lifted their price target on ANI Pharmaceuticals by $9, reflecting updated expectations around revenue growth, profit margin, and future P/E assumptions highlighted in recent Street research. Analyst Commentary While the updated target reflects renewed confidence in revenue and margin assumptions, bearish analysts are still flagging several areas where expectations may be running ahead of what the company can reasonably deliver.
ナラティブの更新 • Mar 25
ANIP: Higher 2026 Guidance And Margin Outlook Will Support Stronger Earnings Power
Analysts have raised their price target on ANI Pharmaceuticals by $9 to $110.63, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligned with updated expectations for revenue and margin performance, which they factor into their cash flow and earnings models.ナラティブの更新 • Mar 11
ANIP: Higher 2026 Guidance Will Test Assumed Margin Expansion
Analysts have lifted their price target on ANI Pharmaceuticals by $9, citing updated assumptions for revenue growth, profit margins, and a revised future P/E multiple that together reshape their view of the stock's long term earnings power. Analyst Commentary While the higher price target reflects updated assumptions, bearish analysts are also flagging several risks that could limit upside if execution or market conditions do not line up with those assumptions.ナラティブの更新 • Feb 24
ANIP: Higher 2026 Revenue Guidance Will Support Richer Forward P/E Multiple
Analysts have lifted their price target on ANI Pharmaceuticals by $9, reflecting updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the US$9 price target increase as a sign that updated revenue assumptions support a higher valuation multiple on forward earnings.ナラティブの更新 • Feb 10
ANIP: Higher 2026 Revenue Outlook And Refined P/E Framework Will Support Upside
Analysts have raised their price target on ANI Pharmaceuticals by about $1 to $110.50, citing updated views on revenue growth, profit margins, discount rate, and future P/E assumptions reflected in recent research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$110.50 target as better aligned with updated assumptions on revenue and margins, suggesting the stock now reflects their latest fundamental work more closely.ナラティブの更新 • Jan 26
ANIP: Future Outlook Will Balance Higher Guidance Expectations And Execution Risks
Analysts have raised their price target on ANI Pharmaceuticals by $9, citing updated expectations for revenue growth, profit margins, and a slightly lower future P/E as key drivers of their revised view. Analyst Commentary While the higher price target signals some confidence around updated revenue and margin expectations, bearish analysts are still flagging areas where the risk and reward profile may feel less attractive for new money.ナラティブの更新 • Jan 12
ANIP: Raised Revenue Outlook And Pipeline Update Will Support Further Upside
Narrative Update on ANI Pharmaceuticals Analysts have trimmed their price target on ANI Pharmaceuticals to about $109.25 from roughly $109.88, citing updated assumptions around slightly higher revenue growth expectations, a modestly lower profit margin outlook, and a small adjustment in the forward P/E multiple. What’s in the News ANI Pharmaceuticals raised its full year 2025 net revenue guidance to a range of US$854 million to US$873 million, compared with prior guidance of US$818 million to US$843 million (Key Developments).ナラティブの更新 • Dec 26
ANIP: Future Outlook Will Balance Corticotropin Momentum And Concentration Risks
Analysts have raised their price target on ANI Pharmaceuticals to $90 from $77, citing continued momentum from Cortrophin Gel, record Q2 sales of $82M, and a 20% full year guidance increase that supports expectations for sustained growth. Analyst Commentary Bearish analysts acknowledge that the higher $90 price target reflects recent strength, but they emphasize that the rating remains at Hold, signaling caution around near term upside.ナラティブの更新 • Dec 12
ANIP: Future Outlook Balances Corticotropin Market Expansion And Competitive Uncertainties
Analysts have lifted their fair value estimate for ANI Pharmaceuticals to $90 from $77 per share as they factor in stronger than expected Cortrophin Gel momentum, higher sales visibility, and an expanding addressable market, despite slightly more conservative growth and margin assumptions. Analyst Commentary Recent Street research reflects a growing divide between optimistic expectations for Cortrophin Gel and a more cautious stance from bearish analysts who question the durability of current momentum and the stock's valuation profile.ナラティブの更新 • Nov 26
ANIP: Continued Momentum Will Drive Upside as Market Opportunities Expand
Analysts have raised their price targets for ANI Pharmaceuticals, with increases ranging from $13 to $28 per share. They cite strong Cortrophin Gel sales momentum, expanded market opportunities, and resilient fundamentals as key factors driving the company’s continued growth outlook.ナラティブの更新 • Nov 10
ANIP: Sustained Revenue Expansion Will Drive Momentum Amid Increasing Market Opportunities
Analysts have increased their average price target for ANI Pharmaceuticals from $105 to approximately $109.88, citing robust Cortrophin Gel performance, expanded market opportunities, and a strengthened revenue outlook. Analyst Commentary Industry analysts are closely monitoring ANI Pharmaceuticals following a series of price target increases.ナラティブの更新 • Sep 25
Expanding ACTH Potential And Rare Disease Markets Will Evolve
ANI Pharmaceuticals’ price target was raised to $105.00 as analysts cite robust Cortrophin Gel prescription trends, a significantly expanded addressable market, and outstanding Q2 revenue growth. Analyst Commentary Bullish analysts highlight that Cortrophin Gel prescription data is consistently surpassing forecasts, indicating stronger-than-expected demand.ナラティブの更新 • Aug 10
Expanding ACTH Potential And Rare Disease Markets Will Evolve
Despite a meaningful reduction in consensus revenue growth forecasts, ANI Pharmaceuticals’ future P/E multiple has declined, improving perceived value and contributing to an upward revision of the consensus analyst price target from $81.38 to $85.75. What's in the News ANI Pharmaceuticals raised 2025 earnings guidance to $818–$843 million from prior $768–$793 million.分析記事 • Aug 10
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement
NasdaqGM:ANIP 1 Year Share Price vs Fair Value Explore ANI Pharmaceuticals's Fair Values from the Community and select...分析記事 • Jun 21
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • May 16
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation
Key Insights ANI Pharmaceuticals' Annual General Meeting to take place on 22nd of May Total pay for CEO Nikhil Lalwani...分析記事 • Mar 28
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) shareholders have had their patience rewarded with a 25% share price jump in...分析記事 • Feb 25
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 11
ANI Pharmaceuticals: More Than Just A Generics Company
Summary ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. The company's debt restructuring and diversified revenue streams enhance financial stability, making it a potential buyout target in the specialty pharma sector. Read the full article on Seeking Alpha分析記事 • Dec 18
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 2x ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ) is a stock...分析記事 • Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Nov 02
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Summary Several actions or omissions by ANIP is consistent with them being acquired and being restricted in what they can disclose. Offer could exceed $8 billion plus sales based CVRs. Offer likely contingent on FDA approval of NDA filed in Q3 2023 for undisclosed drug filed by ANIP but application appears to be financed by undisclosed partner. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Summary Today, we revisit small biopharma ANI Pharmaceuticals, as it is a GARP stock trading near technical support, with solid growth prospects. The company recently acquired Alimera Sciences for $380 million, boosting its rare disease segment with a couple of durable ophthalmology products. Analyst firms are generally bullish on the company's prospects and the stock trades at 12 times trailing earnings, despite revenue growth in the high teens. An analysis of ANIP follows in the paragraphs below. Read the full article on Seeking Alpha
新しいナラティブ • Sep 15
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.分析記事 • Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...分析記事 • Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) robust earnings report didn't manage to move the market for its stock. Our...分析記事 • Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 02
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Summary ANIP has three 505(b)(2) NDA submissions under FDA review, including oral liquid terazosin, female testosterone drug, and oral liquid hydrochlorothiazide. Potential peak sales for Tezruly and hydrochlorothiazide in the US could exceed $500 million, while the female testosterone drug could generate $290 million in royalties. ANIP's revenue could reach $1.41 billion in sales and $290 million in royalties by 2028, with significant growth potential. Read the full article on Seeking Alpha分析記事 • Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
There wouldn't be many who think ANI Pharmaceuticals, Inc.'s ( NASDAQ:ANIP ) price-to-sales (or "P/S") ratio of 2.5x is...Seeking Alpha • Jun 10
ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Summary ANIP's potential royalty revenue from two upcoming drug applications could generate $415 million annually, not reflected in the current share price. ANI Pharmaceuticals' legal action against CG Oncology could result in royalties for Cretostimogene, potentially adding $125 million per year. The Company's female testosterone drug could generate royalties of $290 million per year, with potential for additional indications and international sales. Read the full article on Seeking Alpha収支内訳
収支内訳
ANI Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Mar 26 | 924 | 84 | 313 | 52 |
| 31 Dec 25 | 883 | 70 | 316 | 52 |
| 30 Sep 25 | 827 | 34 | 299 | 56 |
| 30 Jun 25 | 747 | -14 | 292 | 54 |
| 31 Mar 25 | 674 | -22 | 260 | 45 |
| 31 Dec 24 | 614 | -20 | 232 | 45 |
| 30 Sep 24 | 555 | -9 | 211 | 38 |
| 30 Jun 24 | 539 | 24 | 184 | 39 |
| 31 Mar 24 | 517 | 31 | 173 | 39 |
| 31 Dec 23 | 487 | 15 | 162 | 34 |
| 30 Sep 23 | 449 | 10 | 141 | 30 |
| 30 Jun 23 | 401 | -8 | 129 | 26 |
| 31 Mar 23 | 359 | -28 | 122 | 23 |
| 31 Dec 22 | 316 | -50 | 124 | 22 |
| 30 Sep 22 | 283 | -69 | 112 | 20 |
| 30 Jun 22 | 251 | -65 | 99 | 15 |
| 31 Mar 22 | 226 | -63 | 86 | 14 |
| 31 Dec 21 | 216 | -43 | 84 | 11 |
| 30 Sep 21 | 212 | -22 | 61 | 12 |
| 30 Jun 21 | 213 | -17 | 66 | 16 |
| 31 Mar 21 | 213 | -15 | 62 | 13 |
| 31 Dec 20 | 208 | -23 | 65 | 16 |
| 30 Sep 20 | 199 | -24 | 65 | 17 |
| 30 Jun 20 | 198 | -20 | 57 | 15 |
| 31 Mar 20 | 203 | -1 | 56 | 19 |
| 31 Dec 19 | 207 | 6 | 56 | 20 |
| 30 Sep 19 | 216 | 16 | 55 | 18 |
| 30 Jun 19 | 215 | 17 | 53 | 17 |
| 31 Mar 19 | 208 | 14 | 48 | 18 |
| 31 Dec 18 | 202 | 15 | 44 | 15 |
| 30 Sep 18 | 192 | 0 | 40 | 13 |
| 30 Jun 18 | 189 | 0 | 36 | 11 |
| 31 Mar 18 | 187 | 0 | 33 | 10 |
| 31 Dec 17 | 177 | -1 | 32 | 9 |
| 30 Sep 17 | 168 | 7 | 30 | 7 |
| 30 Jun 17 | 158 | 5 | 29 | 5 |
| 31 Mar 17 | 145 | 4 | 28 | 4 |
| 31 Dec 16 | 129 | 4 | 27 | 3 |
| 30 Sep 16 | 108 | 8 | 25 | 3 |
| 30 Jun 16 | 90 | 10 | 23 | 3 |
| 31 Mar 16 | 78 | 12 | 22 | 3 |
| 31 Dec 15 | 76 | 15 | 21 | 3 |
| 30 Sep 15 | 79 | 33 | 20 | 3 |
| 30 Jun 15 | 77 | 35 | 19 | 3 |
質の高い収益: ANIPには$25.4M } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。
利益率の向上: ANIP過去に利益を上げました。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ANIP過去 5 年間で収益を上げており、収益は年間53.5%増加しています。
成長の加速: ANIPは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。
収益対業界: ANIP昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。
株主資本利益率
高いROE: ANIPの 自己資本利益率 ( 16.4% ) は 低い とみなされます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/24 01:01 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
ANI Pharmaceuticals, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |